Assembly Biosciences, Inc.

BST:V7B Stock Report

Market Cap: €97.2m

Assembly Biosciences Management

Management criteria checks 3/4

Assembly Biosciences' CEO is Jason Okazaki, appointed in Aug 2022, has a tenure of 2.42 years. total yearly compensation is $1.37M, comprised of 43.7% salary and 56.3% bonuses, including company stock and options. directly owns 0.21% of the company’s shares, worth €203.55K. The average tenure of the management team and the board of directors is 4.2 years and 5 years respectively.

Key information

Jason Okazaki

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage43.7%
CEO tenure2.4yrs
CEO ownership0.2%
Management average tenure4.2yrs
Board average tenure5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jason Okazaki's remuneration changed compared to Assembly Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$41m

Jun 30 2024n/an/a

-US$46m

Mar 31 2024n/an/a

-US$51m

Dec 31 2023US$1mUS$600k

-US$61m

Sep 30 2023n/an/a

-US$73m

Jun 30 2023n/an/a

-US$81m

Mar 31 2023n/an/a

-US$89m

Dec 31 2022US$2mUS$555k

-US$93m

Sep 30 2022n/an/a

-US$131m

Jun 30 2022n/an/a

-US$127m

Mar 31 2022n/an/a

-US$126m

Dec 31 2021US$1mUS$533k

-US$130m

Sep 30 2021n/an/a

-US$109m

Jun 30 2021n/an/a

-US$94m

Mar 31 2021n/an/a

-US$63m

Dec 31 2020US$4mUS$394k

-US$62m

Compensation vs Market: Jason's total compensation ($USD1.37M) is above average for companies of similar size in the German market ($USD465.04K).

Compensation vs Earnings: Jason's compensation has been consistent with company performance over the past year.

CEO

Jason Okazaki (48 yo)

2.4yrs

Tenure

US$1,373,710

Compensation

Mr. Jason A. Okazaki serves as Chief Executive Officer and Director at Assembly Biosciences, Inc. since January 01, 2023. He served as Chief Operating Officer of Assembly Biosciences, Inc. since August 1,...

Leadership Team

NamePositionTenureCompensationOwnership
Jason Okazaki
CEO, President & Director2.4yrsUS$1.37m0.21%
€ 203.5k
William Delaney
Chief Scientific Officer4yrsUS$811.82k0.16%
€ 151.9k
Nicole White
Chief Manufacturing Officer4.2yrsUS$705.51k0.17%
€ 165.5k
Uri Lopatin
Co-Founder and Clinical & Scientific Advisor10.5yrsUS$1.50mno data
Adam Zlotnick
Co-Founderno datano datano data
Jeanette Bjorkquist
Executive Director of Accounting & Treasuryno datano data0.026%
€ 25.3k
Shannon Ryan
Senior Vice President of Investor Relationsno datano datano data
Jennifer Troia
Chief Human Resources Officer7.2yrsno datano data
Anuj Gaggar
Chief Medical Officer1.2yrsno datano data
Thomas Rollins
Executive Officer6.8yrsUS$652.02kno data
Amy Figueroa
Investor Relations Consultantno datano datano data

4.2yrs

Average Tenure

52yo

Average Age

Experienced Management: V7B's management team is considered experienced (4.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jason Okazaki
CEO, President & Director2yrsUS$1.37m0.21%
€ 203.5k
Adam Zlotnick
Co-Founder10.5yrsno datano data
Anthony Altig
Independent Director13yrsUS$79.58k0.010%
€ 10.2k
William Ringo
Independent Non-Executive Chairman10.5yrsUS$122.08k0.023%
€ 22.2k
John McHutchison
Director5.4yrsUS$64.58k0.25%
€ 238.7k
Susan Mahony
Independent Director7.1yrsUS$74.58k0%
€ 0
Gina Consylman
Independent Director4.3yrsUS$72.08k0%
€ 0
Antonio Bertoletti
Member of Scientific Advisory Board5yrsno datano data
Edward Gane
Member of Scientific Advisory Board5yrsno datano data
Patrick Kennedy
Member of Scientific Advisory Board5yrsno datano data
Alex Thompson
Member of Scientific Advisory Board5yrsno datano data
Stephan Urban
Member of Scientific Advisory Board5yrsno datano data

5.0yrs

Average Tenure

63.5yo

Average Age

Experienced Board: V7B's board of directors are considered experienced (5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 17:58
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Assembly Biosciences, Inc. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Raymond DeaconBrean Capital
Madhu KumarB. Riley Securities, Inc.